Implementing lung cancer screening: the US experience

The reduced lung cancer mortality observed with low-dose computed tomography (LDCT) screening in the National Lung Screening Trial (NLST) has led to annual screening in the United States as a covered benefit by both private insurers and the federal health insurance programme, the Centers for Medicare and Medicaid Services. Reimbursement for screening requires data submission to a federal registry on all individuals, whether privately or federally insured. Data must document individual patient eligibility as well as shared decision-making regarding the benefits and risks of LDCT screening, smoking cessation counselling, and the importance of annual screening. Beyond these requirements lie opportunities to maximise the benefits of screening in the radiology setting. Individuals eligible for screening account for a minority of those diagnosed with lung cancer in the US; the evidence needed to improve patient selection must be collected systematically for both screen-detected and incidentally detected lung nodules. Current nodule management and tracking guidelines reduce the falsepositive rates observed in the NLST, but fall short in their ability to correctly classify nodules as benign or malignant. Smoking cessation is inadequately managed in most busy clinician practices. As a common nidus for tobacco-associated lung diseases, imagers are uniquely poised to collect the longitudinal data to better inform screening eligibility and to improve indeterminate nodule management, while maximising the setting of screening to motivate and provide smoking cessation. By re-engineering the notion of imaging practice, radiologists can be major contributors to lung cancer early detection and mortality reduction. (C) 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.